Cytek Biosciences, Inc.: Form 10-Q for the period ended Mar 31, 2025
Filed with the SEC on May 8, 2025 and accepted by EDGAR at May 8, 2025, 17:21 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-01-01 to 2025-03-31 | $41.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2025-01-01 to 2025-03-31 | $21.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2025-01-01 to 2025-03-31 | $20.2m | us-gaap:GrossProfit |
| Research and development | 3 months2025-01-01 to 2025-03-31 | $9.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2025-01-01 to 2025-03-31 | −$15.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2025-01-01 to 2025-03-31 | $291.0k | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2025-01-01 to 2025-03-31 | $136.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-01-01 to 2025-03-31 | −$11.4m | us-gaap:NetIncomeLoss |
| Diluted shares (weighted) | 3 months2025-01-01 to 2025-03-31 | 128,339,481 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2025-01-01 to 2025-03-31 | −$125.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2025-01-01 to 2025-03-31 | $849.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 3 months2025-01-01 to 2025-03-31 | $10.6m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2025-03-31 | $95.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-03-31 | $380.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-03-31 | $482.6m | us-gaap:Assets |
| Current liabilities | At period end2025-03-31 | $67.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-03-31 | $103.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-03-31 | $379.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-25-023927. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.